compounds that can act as antagonists for thromboxane (Figure 11.3(b) ). It was
found that significant antagonist activity is obtained when:
1. at position 2 there is a substituentcisto the other substituents of the dioxan
ring,
2. the phenolic and alkenoic acid side chains at positions 5 and 6 have acis
orientation and
3. the C¼C of the alkenoic acid side chain has acisconfiguration.
These active analogues were initially synthesized in gram quantities by routes
that allowed numerous analogues to be produced for the preliminary biological
evaluation (Figure 11.4).
O
O
H 3 C
H 3 C
O
O
H 3 C
H 3 C
H 3 CO
The product is a
mixture of
Ozonolysis stereoisomers (B).
O
O
O
H 3 C
H 3 C
H 3 CO
O
O
H 3 C
H 3 C
H 3 CO
COOH
H 3 C
H 3 C
O
O
COOH
HO
ICI 180080
NaSEt
Separation of
the stereoisomers
of mixture B by
chromatography.
Wittig
reaction
Ph 3 P(CH 2 ) 4 COOH
Br−
+
Diethyl
allylmalonate
Treatment of the magnesium enolate
of diethyl malonate with an aroyl
halide, followed by decarboxylation
EtOOC
O
H 3 CO
Various
reducing agents
HO
HO
H 3 CO
The product is a
mixture of
stereoisomers (A).
OCH 3
Dimethoxypropane,
the acetal of acetone
This reaction was carried
out on the mixture A
produced in the previous
stage.
COOEt
EtOOC
H 3 CO
COCl
Aroyl chlorides
Variations in the phenyl
substituents were introduced
at this stage.
H 3 CO
H 3 CO
Figure 11.4 An outline of the initial research route for the synthesis of ICI 180080 and other
analogues. The intermediates and products were produced as racemates. Geometric stereoisomers
were synthesized as shown in the reaction scheme.
The potential manufacturing route for the active thromboxane antagonists
synthesized by the small scale route outlined in Figure 11.4 must include a way
of controlling the stereochemistry of the product that will also give a single
enantiomer. In addition, it must also include alternatives to the chromato-
graphic separation, since this technique is not practical on a large scale, the
CHEMICAL DEVELOPMENT 229